Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism.

Michael B Fisher1, Kirk R Henne, Jason Boer

  • 1Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA. mfisher2@rdg.boehringer-ingelheim.com

Current Opinion in Drug Discovery & Development
|February 1, 2006
PubMed
Summary

Medicinal chemists aim to reduce drug clearance by blocking cytochrome P450 (CYP) metabolism. However, blocking one metabolic pathway may not decrease overall drug clearance due to compensatory metabolism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases.

Journal of medicinal chemistry·2026
Same author

Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends.

Clinical pharmacology and therapeutics·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates (<u>PART 1A</u> - Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing & Reporting <u>PART 1B</u> - Regulatory Agencies' Input on Regulated Bioanalysis/BMV).

Bioanalysis·2026
Same author

Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework.

Clinical pharmacology and therapeutics·2025
Same author

Adapting a safe water storage container to improve household stored water quality in rural Burkina Faso: a cluster randomized trial.

Journal of water, sanitation, and hygiene for development : a journal of the International Water Association·2025
Same author

DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response.

eLife·2024

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Drug Metabolism

Background:

  • Cytochromes P450 (CYPs) mediate the majority of oxidative drug metabolism.
  • Drug discovery often involves synthesizing analogs to reduce metabolic clearance.
  • Blocking specific CYP metabolic sites is a common strategy to reduce drug clearance.

Purpose of the Study:

  • To present the concepts and evidence behind the phenomenon of compensatory metabolism.
  • To explain the complexities encountered when attempting to block metabolic clearance.
  • To discuss strategies for modifying drug molecules to reduce CYP metabolism.

Main Methods:

  • Review of existing literature on drug metabolism and CYP inhibition.
  • Analysis of case studies demonstrating compensatory metabolic pathways.

Related Experiment Videos

  • Discussion of chemical modification strategies, including fluorination and deuteration.

    • Main Results:

    • Blocking a single metabolic pathway via chemical modification (e.g., fluorination) does not always reduce overall drug clearance.
    • Metabolic activity can be rerouted to alternative pathways, maintaining substrate consumption rates.
    • The rate of formation of alternative metabolites may increase to compensate for the blocked pathway.

    Conclusions:

    • Strategies aimed at blocking specific CYP metabolic sites may not effectively reduce overall drug clearance.
    • Understanding compensatory metabolism is crucial for successful drug design and development.
    • Medicinal chemists must consider the potential for alternative metabolic pathways when designing drug analogs to reduce clearance.